Time filter

Source Type

PMC brings >20 years of expertise, research, studies, trials and insights developed in conjunction with NASA and the Department of Defense More than $30 million invested culminating in the issuance of 10 major patents across a range of benefits and need states for consumers Health Sciences Division now has the credibility and science underpinning a range of planned launches for the medical and pharmacy channels DENVER, CO / ACCESSWIRE / May 18, 2017 / New Age Beverages Corporation (NASDAQ: NBEV) the Colorado-based leading all-natural healthy functional beverage company whose brands include XingTea®, XingEnergy ®, Aspen Pure®, Búcha® Live Kombucha, Marley One Drop®, Marley Mellow Mood®, and CocoLibre® today announced the acquisition of Premier Micronutrient Corporation. The acquisition catapults the Company's Health Sciences Division and New Age's plans to develop the next generation of healthy functional beverages. The intellectual property addition of more than 10 major patents and patents pending significantly increases New Age's intangible assets and underpins the Company's planned portfolio launches targeted to the medical and pharmacy channels. One of the major drivers of growth that the Company recently shared with investors was the penetration of new, less competitively intense channels and market segments where our primary competitors do not operate. The Company has also always had on its roadmap the intent to redefine healthy functional beverages from the currently pervasive less bad or less sweet offerings, to beverages that can make a fundamental difference in improving everyday human life. The acquisition of Premier Micronutrient Corporation (PMC) and their wealth of patents, studies, research, clinical trial insight, science and medical expertise provides the foundation for and credibility behind New Age's planned penetration of the medical and pharmacy channels with a portfolio of truly healthy functional beverages. Dr. Jerry Haase, Chief Scientific Officer of New Age Beverage's Health Sciences Division commented, "As an internationally known clinician and medical researcher, I always seek unique opportunities to broadly impact human health. I am especially enthusiastic to join New Age concurrent with the acquisition of PMC, because of the Company's compelling vision to create the greatest healthy functional beverage enterprise in the world. We will expand upon our intellectual property portfolio and develop product platforms to address novel categories of public interest and need. We also anticipate leveraging our extensive relationships in the health care community to credibly promote New Age's medical product portfolio's acceptance in the global medical marketplace." "Use of Multiple Antioxidant Micronutrients as 1) US Navy CRADA - NMRC-06-2338 "Investigations into the Efficacy of an Antioxidant-containing Micronutrient Formulation for the Treatment of Hearing Loss and Balance Disorders Associated with Blast Injuries." 2) US Navy CRADA - NMRC-06-2383 "The Effects of Antioxidant Supplementation to Protect Against Cold at High Altitude." 3) US Army CRADA - W81XWH-07-0321 "Efficacy of Multiple Antioxidants in Reducing Damage Produced by Mustard Gas." 4) US Army CRADA - W81XWH-08-2007 "Efficacy of Multiple Antioxidants in reducing Damage Produced by Nerve Agents." 5) Space Act Agreement - NASA "Development of a Successful Protection Formula Against Radiation-Induced Oxidative Injury in Vulnerable Populations." 6) US Army CRADA - W91YTZ-10-P-0773 "Evaluation of Micronutrients in Combination with Standard Therapy in the Management of Type 2 Diabetes." 7) US Army CRADA - W81XWH-11-10746 "Efficacy of Multiple Antioxidants in Combination with Standard Therapy in Reducing VX-Induced Seizures and Associated Behavior Changes." In addition to the wealth of patents, patents pending, and cooperative research and development agreements, PMC has conducted over 14 prospective human clinical trials and animal studies validating the efficacy of their formulas and products. That body of work developed over the past 20 years in conjunction with the Department of Defense and NASA have formed the basis for justifying their distinctiveness leading to the issuance of their patents, and demonstrated their proven benefit for a range of human need states including: New Age Beverages acquired 100% of the assets and interests of Premier Micronutrient Corporation, their portfolio of products, their intellectual property, and the formulas for existing and envisioned healthy functional beverage products for the pharmacy, medical, sports, military, and other channels. Specific terms of the transaction were not disclosed, with the final closing of the transaction subject to certain closing conditions and expected to be complete within 30 days. Brent Willis, Chief Executive Officer of New Age Beverages remarked, "We made a commitment that we would make a difference for consumers with truly healthy, functional beverages. We believe the world doesn't need another slightly less bad carbonated soft drink or more drinkable sports drink. With the internalization of the expertise and insights from PMC we will compete in a spectrum that our major competitors are not in, and not even contemplating. Beverages are a significantly more efficacious and patient friendly delivery system than pills for example, just no one has done it, and we intend to be the first." Premier Micronutrient Corporation (PMC) was founded in 2000 to develop formulations in cooperation with the Department of Defense and NASA. Since inception, PMC has worked with the Marine Corps Systems Command that contracted PMC to adapt its formulations to protect high-risk military personnel. PMC operated for more than 10 years developing protective products and conducting research for the Department of Defense. PMC received Congressional support leading to eleven studies that have demonstrated the validity of PMC's formulations to decrease oxidative damage, improve immune function, reduce inflammation, protect against neurologic symptoms and recovery from concussions, recovery from hearing and balance disorders, reversal of vascular disease and lipid abnormalities, and protect against hostile environmental factors such as radiation. The products have been shown to be completely safe in all studies and in more than 10 years of public consumption. New Age Beverages Corporation is a Colorado-based, leading all-natural tea and healthy functional beverage company that was founded in 2003. The Company competes in the fast growing healthy functional beverage segments including Ready to Drink (RTD) Tea, RTD Coffee, Kombucha, Energy Drinks, Relaxation Drinks, Coconut Waters and Functional Waters with the brands XingTea®, Marley One Drop®, Búcha® Live Kombucha, XingEnergy®, Marley Mellow Mood®, Coco-Libre®, and Aspen Pure® PH and Aspen Pure® Probiotic Water. The Company's brands are sold across all 50 states within the US and in more than 10 countries internationally across all channels via direct and store door distribution systems. The company operates the websites www.newagebev.us, www.newagehealth.us, www.mybucha.com, www.xingtea.com, www.aspenpure.com, www.drinkmarley.com, and www.cocolibre.com. This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company including statements regarding New Age Beverage's expectation to see continued growth. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. New Age Beverages competes in a rapidly growing and transforming industry, and other factors disclosed in the Company's filings with the Securities and Exchange Commission might affect the Company's operations. Unless required by applicable law, nBev undertakes no obligation to update or revise any forward-looking statements. For investor inquiries about New Age Beverages Corporation please contact: PMC brings >20 years of expertise, research, studies, trials and insights developed in conjunction with NASA and the Department of Defense More than $30 million invested culminating in the issuance of 10 major patents across a range of benefits and need states for consumers Health Sciences Division now has the credibility and science underpinning a range of planned launches for the medical and pharmacy channels DENVER, CO / ACCESSWIRE / May 18, 2017 / New Age Beverages Corporation (NASDAQ: NBEV) the Colorado-based leading all-natural healthy functional beverage company whose brands include XingTea®, XingEnergy ®, Aspen Pure®, Búcha® Live Kombucha, Marley One Drop®, Marley Mellow Mood®, and CocoLibre® today announced the acquisition of Premier Micronutrient Corporation. The acquisition catapults the Company's Health Sciences Division and New Age's plans to develop the next generation of healthy functional beverages. The intellectual property addition of more than 10 major patents and patents pending significantly increases New Age's intangible assets and underpins the Company's planned portfolio launches targeted to the medical and pharmacy channels. One of the major drivers of growth that the Company recently shared with investors was the penetration of new, less competitively intense channels and market segments where our primary competitors do not operate. The Company has also always had on its roadmap the intent to redefine healthy functional beverages from the currently pervasive less bad or less sweet offerings, to beverages that can make a fundamental difference in improving everyday human life. The acquisition of Premier Micronutrient Corporation (PMC) and their wealth of patents, studies, research, clinical trial insight, science and medical expertise provides the foundation for and credibility behind New Age's planned penetration of the medical and pharmacy channels with a portfolio of truly healthy functional beverages. Dr. Jerry Haase, Chief Scientific Officer of New Age Beverage's Health Sciences Division commented, "As an internationally known clinician and medical researcher, I always seek unique opportunities to broadly impact human health. I am especially enthusiastic to join New Age concurrent with the acquisition of PMC, because of the Company's compelling vision to create the greatest healthy functional beverage enterprise in the world. We will expand upon our intellectual property portfolio and develop product platforms to address novel categories of public interest and need. We also anticipate leveraging our extensive relationships in the health care community to credibly promote New Age's medical product portfolio's acceptance in the global medical marketplace." "Use of Multiple Antioxidant Micronutrients as 1) US Navy CRADA - NMRC-06-2338 "Investigations into the Efficacy of an Antioxidant-containing Micronutrient Formulation for the Treatment of Hearing Loss and Balance Disorders Associated with Blast Injuries." 2) US Navy CRADA - NMRC-06-2383 "The Effects of Antioxidant Supplementation to Protect Against Cold at High Altitude." 3) US Army CRADA - W81XWH-07-0321 "Efficacy of Multiple Antioxidants in Reducing Damage Produced by Mustard Gas." 4) US Army CRADA - W81XWH-08-2007 "Efficacy of Multiple Antioxidants in reducing Damage Produced by Nerve Agents." 5) Space Act Agreement - NASA "Development of a Successful Protection Formula Against Radiation-Induced Oxidative Injury in Vulnerable Populations." 6) US Army CRADA - W91YTZ-10-P-0773 "Evaluation of Micronutrients in Combination with Standard Therapy in the Management of Type 2 Diabetes." 7) US Army CRADA - W81XWH-11-10746 "Efficacy of Multiple Antioxidants in Combination with Standard Therapy in Reducing VX-Induced Seizures and Associated Behavior Changes." In addition to the wealth of patents, patents pending, and cooperative research and development agreements, PMC has conducted over 14 prospective human clinical trials and animal studies validating the efficacy of their formulas and products. That body of work developed over the past 20 years in conjunction with the Department of Defense and NASA have formed the basis for justifying their distinctiveness leading to the issuance of their patents, and demonstrated their proven benefit for a range of human need states including: New Age Beverages acquired 100% of the assets and interests of Premier Micronutrient Corporation, their portfolio of products, their intellectual property, and the formulas for existing and envisioned healthy functional beverage products for the pharmacy, medical, sports, military, and other channels. Specific terms of the transaction were not disclosed, with the final closing of the transaction subject to certain closing conditions and expected to be complete within 30 days. Brent Willis, Chief Executive Officer of New Age Beverages remarked, "We made a commitment that we would make a difference for consumers with truly healthy, functional beverages. We believe the world doesn't need another slightly less bad carbonated soft drink or more drinkable sports drink. With the internalization of the expertise and insights from PMC we will compete in a spectrum that our major competitors are not in, and not even contemplating. Beverages are a significantly more efficacious and patient friendly delivery system than pills for example, just no one has done it, and we intend to be the first." Premier Micronutrient Corporation (PMC) was founded in 2000 to develop formulations in cooperation with the Department of Defense and NASA. Since inception, PMC has worked with the Marine Corps Systems Command that contracted PMC to adapt its formulations to protect high-risk military personnel. PMC operated for more than 10 years developing protective products and conducting research for the Department of Defense. PMC received Congressional support leading to eleven studies that have demonstrated the validity of PMC's formulations to decrease oxidative damage, improve immune function, reduce inflammation, protect against neurologic symptoms and recovery from concussions, recovery from hearing and balance disorders, reversal of vascular disease and lipid abnormalities, and protect against hostile environmental factors such as radiation. The products have been shown to be completely safe in all studies and in more than 10 years of public consumption. New Age Beverages Corporation is a Colorado-based, leading all-natural tea and healthy functional beverage company that was founded in 2003. The Company competes in the fast growing healthy functional beverage segments including Ready to Drink (RTD) Tea, RTD Coffee, Kombucha, Energy Drinks, Relaxation Drinks, Coconut Waters and Functional Waters with the brands XingTea®, Marley One Drop®, Búcha® Live Kombucha, XingEnergy®, Marley Mellow Mood®, Coco-Libre®, and Aspen Pure® PH and Aspen Pure® Probiotic Water. The Company's brands are sold across all 50 states within the US and in more than 10 countries internationally across all channels via direct and store door distribution systems. The company operates the websites www.newagebev.us, www.newagehealth.us, www.mybucha.com, www.xingtea.com, www.aspenpure.com, www.drinkmarley.com, and www.cocolibre.com. This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company including statements regarding New Age Beverage's expectation to see continued growth. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. New Age Beverages competes in a rapidly growing and transforming industry, and other factors disclosed in the Company's filings with the Securities and Exchange Commission might affect the Company's operations. Unless required by applicable law, nBev undertakes no obligation to update or revise any forward-looking statements. For investor inquiries about New Age Beverages Corporation please contact:


DENVER, CO / ACCESSWIRE / May 18, 2017 / New Age Beverages Corporation (NASDAQ: NBEV) the Colorado-based leading all-natural healthy functional beverage company whose brands include XingTea®, XingEnergy ®, Aspen Pure®, Búcha® Live Kombucha, Marley One Drop®, Marley Mellow Mood®, and CocoLibre® today announced the acquisition of Premier Micronutrient Corporation. The acquisition catapults the Company's Health Sciences Division and New Age's plans to develop the next generation of healthy functional beverages. The intellectual property addition of more than 10 major patents and patents pending significantly increases New Age's intangible assets and underpins the Company's planned portfolio launches targeted to the medical and pharmacy channels. One of the major drivers of growth that the Company recently shared with investors was the penetration of new, less competitively intense channels and market segments where our primary competitors do not operate. The Company has also always had on its roadmap the intent to redefine healthy functional beverages from the currently pervasive less bad or less sweet offerings, to beverages that can make a fundamental difference in improving everyday human life. The acquisition of Premier Micronutrient Corporation (PMC) and their wealth of patents, studies, research, clinical trial insight, science and medical expertise provides the foundation for and credibility behind New Age's planned penetration of the medical and pharmacy channels with a portfolio of truly healthy functional beverages. Dr. Jerry Haase, Chief Scientific Officer of New Age Beverage's Health Sciences Division commented, "As an internationally known clinician and medical researcher, I always seek unique opportunities to broadly impact human health. I am especially enthusiastic to join New Age concurrent with the acquisition of PMC, because of the Company's compelling vision to create the greatest healthy functional beverage enterprise in the world. We will expand upon our intellectual property portfolio and develop product platforms to address novel categories of public interest and need. We also anticipate leveraging our extensive relationships in the health care community to credibly promote New Age's medical product portfolio's acceptance in the global medical marketplace." 1) US Navy CRADA - NMRC-06-2338 "Investigations into the Efficacy of an Antioxidant-containing Micronutrient Formulation for the Treatment of Hearing Loss and Balance Disorders Associated with Blast Injuries." 2) US Navy CRADA - NMRC-06-2383 "The Effects of Antioxidant Supplementation to Protect Against Cold at High Altitude." 3) US Army CRADA - W81XWH-07-0321 "Efficacy of Multiple Antioxidants in Reducing Damage Produced by Mustard Gas." 4) US Army CRADA - W81XWH-08-2007 "Efficacy of Multiple Antioxidants in reducing Damage Produced by Nerve Agents." 5) Space Act Agreement - NASA "Development of a Successful Protection Formula Against Radiation-Induced Oxidative Injury in Vulnerable Populations." 6) US Army CRADA - W91YTZ-10-P-0773 "Evaluation of Micronutrients in Combination with Standard Therapy in the Management of Type 2 Diabetes." 7) US Army CRADA - W81XWH-11-10746 "Efficacy of Multiple Antioxidants in Combination with Standard Therapy in Reducing VX-Induced Seizures and Associated Behavior Changes." In addition to the wealth of patents, patents pending, and cooperative research and development agreements, PMC has conducted over 14 prospective human clinical trials and animal studies validating the efficacy of their formulas and products. That body of work developed over the past 20 years in conjunction with the Department of Defense and NASA have formed the basis for justifying their distinctiveness leading to the issuance of their patents, and demonstrated their proven benefit for a range of human need states including: New Age Beverages acquired 100% of the assets and interests of Premier Micronutrient Corporation, their portfolio of products, their intellectual property, and the formulas for existing and envisioned healthy functional beverage products for the pharmacy, medical, sports, military, and other channels. Specific terms of the transaction were not disclosed, with the final closing of the transaction subject to certain closing conditions and expected to be complete within 30 days. Brent Willis, Chief Executive Officer of New Age Beverages remarked, "We made a commitment that we would make a difference for consumers with truly healthy, functional beverages. We believe the world doesn't need another slightly less bad carbonated soft drink or more drinkable sports drink. With the internalization of the expertise and insights from PMC we will compete in a spectrum that our major competitors are not in, and not even contemplating. Beverages are a significantly more efficacious and patient friendly delivery system than pills for example, just no one has done it, and we intend to be the first." Premier Micronutrient Corporation (PMC) was founded in 2000 to develop formulations in cooperation with the Department of Defense and NASA. Since inception, PMC has worked with the Marine Corps Systems Command that contracted PMC to adapt its formulations to protect high-risk military personnel. PMC operated for more than 10 years developing protective products and conducting research for the Department of Defense. PMC received Congressional support leading to eleven studies that have demonstrated the validity of PMC's formulations to decrease oxidative damage, improve immune function, reduce inflammation, protect against neurologic symptoms and recovery from concussions, recovery from hearing and balance disorders, reversal of vascular disease and lipid abnormalities, and protect against hostile environmental factors such as radiation. The products have been shown to be completely safe in all studies and in more than 10 years of public consumption. New Age Beverages Corporation is a Colorado-based, leading all-natural tea and healthy functional beverage company that was founded in 2003. The Company competes in the fast growing healthy functional beverage segments including Ready to Drink (RTD) Tea, RTD Coffee, Kombucha, Energy Drinks, Relaxation Drinks, Coconut Waters and Functional Waters with the brands XingTea®, Marley One Drop®, Búcha® Live Kombucha, XingEnergy®, Marley Mellow Mood®, Coco-Libre®, and Aspen Pure® PH and Aspen Pure® Probiotic Water. The Company's brands are sold across all 50 states within the US and in more than 10 countries internationally across all channels via direct and store door distribution systems. The company operates the websites www.newagebev.us, www.newagehealth.us, www.mybucha.com, www.xingtea.com, www.aspenpure.com, www.drinkmarley.com, and www.cocolibre.com. This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company including statements regarding New Age Beverage's expectation to see continued growth. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. New Age Beverages competes in a rapidly growing and transforming industry, and other factors disclosed in the Company's filings with the Securities and Exchange Commission might affect the Company's operations. Unless required by applicable law, nBev undertakes no obligation to update or revise any forward-looking statements. For investor inquiries about New Age Beverages Corporation please contact:


The study was conducted by The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) in collaboration with the National Cancer Centre Singapore and Singapore Clinical Research Institute (SCRI) and supported by the National Medical Council Singapore and Sirtex Medical Limited The lead author of the SIRveNIB abstract, Professor Pierce Chow, Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital, reported that: "Asia Pacific patients with locally advanced primary liver cancer (HCC or hepatocellular carcinoma) with no spread (metastases) outside the liver who are treated with Y-90 resin microspheres have a significantly better tumour response rate (TRR) compared to sorafenib, despite 28.6% (n=52) of patients not receiving Y-90 therapy as planned (TRR - 16.5% for Y-90 resin microspheres vs 1.7% for sorafenib, respectively; p < 0.001).  Moreover, patients experienced fewer, less serious adverse events when compared with those treated with sorafenib. There were no statistically significant differences in the primary endpoint of overall survival (OS) between the two treatments." Although the median OS in the intent-to-treat group[1] was 8.54 months for Y-90 resin microspheres vs. 10.58 months for sorafenib, respectively (p=0.203), there was a trend in improvement in median OS in the treated group[2] for Y-90 resin microspheres (11.27 vs. 10.41 months, p=0.273). While Y-90 resin microspheres were not superior to sorafenib regarding OS, Professor Chow, who is also Professor and Course Director at the Duke-NUS Medical School, indicated that "the better tumour response and tolerability of Y-90 resin microspheres offers a compelling treatment alternative for patients with advanced hepatocellular carcinoma, for whom there are limited treatment options available." SIRveNIB was designed to compare the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium-90 [Y-90] resin microspheres (SIR-Spheres; Sirtex Medical Limited, North Sydney, Australia) versus sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals, Berlin, Germany), a systemic treatment that is the current standard of care in advanced hepatocellular carcinoma. The patients in SIRveNIB were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation. "Each year we are making good progress in treating liver cancer. The deeper we go in our research the better we are able to understand how the cancer behaves and we are able to widen the treatments options for our patients. The results reinforced our belief that with the right people on the research project, we can get the best results. I am grateful to our partners for collaborating in this study," added Professor Soo Khee Chee, Director of NCCS. "Completion of the investigator-led SIRveNIB study represents a significant milestone in Asia Pacific liver cancer research, and underscores the strong private-public partnership that exists between Sirtex Medical Limited, the National Cancer Centre Singapore and Singapore Clinical Research Institute. We look forward to the presentation of more complete results of SIRveNIB at the impending ASCO Annual Meeting," said Associate Professor Teoh Yee Leong, CEO Singapore Clinical Research Institute. "This is the first time we have completed such a large-scale investigator-led clinical trial in the Asia Pacific region, whose results will be beneficial to liver cancer patients in our region." Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer - cancer that starts in the liver - which is the sixth most-common cancer in the world and the second most-common cause of cancer-related death.[3] It affects mainly patients with cirrhosis from any cause, including viral hepatitis and alcohol abuse. HCC occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in the Asia Pacific region and Southern Europe. When diagnosed in its early stages, HCC can be treated by surgical resection, ablation or liver transplantation with expectation of improved long-term survival. However, these options are not available to the great majority of patients. For patients with unresectable HCC, the outlook is bleak, with survival ranging from a few months to about two years depending largely on the extent of their tumours and state of their liver at the time of diagnosis.[4] No new HCC treatment option has been tested successfully in large studies for almost a decade. National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. http://www.nccs.com.sg Singapore Clinical Research Institute (SCRI) is a National Academic Research Organisation dedicated to enhance the standards of human clinical research. Its mission is to spearhead and develop core capabilities, infrastructure and scientific leadership for clinical research in Singapore. SCRI is a national clinical trials coordination centre that works with National Medical Research Council (NMRC) to assist the Ministry of Health in implementing clinical trials policy and strategic initiatives to support and develop clinical research competencies locally. In driving towards its vision, SCRI collaborates with clinicians to enhance Singapore's clinical research and strengthen its expertise in executing multi-site, multi-national studies and the development of regional clinical research networks. SCRI is a wholly-owned subsidiary of MOH Holdings. http://www.scri.edu.sg SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as Turkey, India and Singapore. The product is also supplied for this use in countries such as Hong Kong, Israel, Malaysia, New Zealand, Taiwan and Thailand. SIR-Spheres Y-90 resin microspheres also have a full Pre-Market Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine. [1] Intent-to-treat group includes all patients who were enrolled and randomly allocated to treatment and are analysed according to the group to which they were randomized.  The intent-to-treat-group included n=182 (Y-90 resin microspheres) and n=178 (sorafenib). [2] Treated group includes only those patients who completed the treatment originally allocated.  The treated group included n=130 (Y-90 resin microspheres) and n=162 (sorafenib). [3] Ferlay J et al.  Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr , accessed on 18/May/2017.


The study was conducted by The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) in collaboration with the National Cancer Centre Singapore and Singapore Clinical Research Institute (SCRI) and supported by the National Medical Council Singapore and Sirtex Medical Limited The lead author of the SIRveNIB abstract, Professor Pierce Chow, Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital, reported that: "Asia Pacific patients with locally advanced primary liver cancer (HCC or hepatocellular carcinoma) with no spread (metastases) outside the liver who are treated with Y-90 resin microspheres have a significantly better tumour response rate (TRR) compared to sorafenib, despite 28.6% (n=52) of patients not receiving Y-90 therapy as planned (TRR - 16.5% for Y-90 resin microspheres vs 1.7% for sorafenib, respectively; p < 0.001).  Moreover, patients experienced fewer, less serious adverse events when compared with those treated with sorafenib. There were no statistically significant differences in the primary endpoint of overall survival (OS) between the two treatments." Although the median OS in the intent-to-treat group[1] was 8.54 months for Y-90 resin microspheres vs. 10.58 months for sorafenib, respectively (p=0.203), there was a trend in improvement in median OS in the treated group[2] for Y-90 resin microspheres (11.27 vs. 10.41 months, p=0.273). While Y-90 resin microspheres were not superior to sorafenib regarding OS, Professor Chow, who is also Professor and Course Director at the Duke-NUS Medical School, indicated that "the better tumour response and tolerability of Y-90 resin microspheres offers a compelling treatment alternative for patients with advanced hepatocellular carcinoma, for whom there are limited treatment options available." SIRveNIB was designed to compare the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium-90 [Y-90] resin microspheres (SIR-Spheres; Sirtex Medical Limited, North Sydney, Australia) versus sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals, Berlin, Germany), a systemic treatment that is the current standard of care in advanced hepatocellular carcinoma. The patients in SIRveNIB were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation. "Each year we are making good progress in treating liver cancer. The deeper we go in our research the better we are able to understand how the cancer behaves and we are able to widen the treatments options for our patients. The results reinforced our belief that with the right people on the research project, we can get the best results. I am grateful to our partners for collaborating in this study," added Professor Soo Khee Chee, Director of NCCS. "Completion of the investigator-led SIRveNIB study represents a significant milestone in Asia Pacific liver cancer research, and underscores the strong private-public partnership that exists between Sirtex Medical Limited, the National Cancer Centre Singapore and Singapore Clinical Research Institute. We look forward to the presentation of more complete results of SIRveNIB at the impending ASCO Annual Meeting," said Associate Professor Teoh Yee Leong, CEO Singapore Clinical Research Institute. "This is the first time we have completed such a large-scale investigator-led clinical trial in the Asia Pacific region, whose results will be beneficial to liver cancer patients in our region." Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer - cancer that starts in the liver - which is the sixth most-common cancer in the world and the second most-common cause of cancer-related death.[3] It affects mainly patients with cirrhosis from any cause, including viral hepatitis and alcohol abuse. HCC occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in the Asia Pacific region and Southern Europe. When diagnosed in its early stages, HCC can be treated by surgical resection, ablation or liver transplantation with expectation of improved long-term survival. However, these options are not available to the great majority of patients. For patients with unresectable HCC, the outlook is bleak, with survival ranging from a few months to about two years depending largely on the extent of their tumours and state of their liver at the time of diagnosis.[4] No new HCC treatment option has been tested successfully in large studies for almost a decade. National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. http://www.nccs.com.sg Singapore Clinical Research Institute (SCRI) is a National Academic Research Organisation dedicated to enhance the standards of human clinical research. Its mission is to spearhead and develop core capabilities, infrastructure and scientific leadership for clinical research in Singapore. SCRI is a national clinical trials coordination centre that works with National Medical Research Council (NMRC) to assist the Ministry of Health in implementing clinical trials policy and strategic initiatives to support and develop clinical research competencies locally. In driving towards its vision, SCRI collaborates with clinicians to enhance Singapore's clinical research and strengthen its expertise in executing multi-site, multi-national studies and the development of regional clinical research networks. SCRI is a wholly-owned subsidiary of MOH Holdings. http://www.scri.edu.sg SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as Turkey, India and Singapore. The product is also supplied for this use in countries such as Hong Kong, Israel, Malaysia, New Zealand, Taiwan and Thailand. SIR-Spheres Y-90 resin microspheres also have a full Pre-Market Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine. [1] Intent-to-treat group includes all patients who were enrolled and randomly allocated to treatment and are analysed according to the group to which they were randomized.  The intent-to-treat-group included n=182 (Y-90 resin microspheres) and n=178 (sorafenib). [2] Treated group includes only those patients who completed the treatment originally allocated.  The treated group included n=130 (Y-90 resin microspheres) and n=162 (sorafenib). [3] Ferlay J et al.  Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr , accessed on 18/May/2017.


The SIRveNIB abstract published on-line in the Journal of Clinical Oncology states that treatment of locally advanced Hepatocellular Carcinoma (HCC) with a single treatment of SIR-Spheres® Y-90 resin microspheres results in Overall Survival not significantly different from twice-daily oral sorafenib, but with significantly better tumour response and fewer and less severe adverse events The study was conducted by The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) in collaboration with the National Cancer Centre Singapore and Singapore Clinical Research Institute (SCRI) and supported by the National Medical Council Singapore and Sirtex Medical Limited The lead author of the SIRveNIB abstract, Professor Pierce Chow, Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital, reported that: "Asia Pacific patients with locally advanced primary liver cancer (HCC or hepatocellular carcinoma) with no spread (metastases) outside the liver who are treated with Y-90 resin microspheres have a significantly better tumour response rate (TRR) compared to sorafenib, despite 28.6% (n=52) of patients not receiving Y-90 therapy as planned (TRR - 16.5% for Y-90 resin microspheres vs 1.7% for sorafenib, respectively; p < 0.001).  Moreover, patients experienced fewer, less serious adverse events when compared with those treated with sorafenib. There were no statistically significant differences in the primary endpoint of overall survival (OS) between the two treatments." Although the median OS in the intent-to-treat group[1] was 8.54 months for Y-90 resin microspheres vs. 10.58 months for sorafenib, respectively (p=0.203), there was a trend in improvement in median OS in the treated group[2] for Y-90 resin microspheres (11.27 vs. 10.41 months, p=0.273). While Y-90 resin microspheres were not superior to sorafenib regarding OS, Professor Chow, who is also Professor and Course Director at the Duke-NUS Medical School, indicated that "the better tumour response and tolerability of Y-90 resin microspheres offers a compelling treatment alternative for patients with advanced hepatocellular carcinoma, for whom there are limited treatment options available." SIRveNIB was designed to compare the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium-90 [Y-90] resin microspheres (SIR-Spheres; Sirtex Medical Limited, North Sydney, Australia) versus sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals, Berlin, Germany), a systemic treatment that is the current standard of care in advanced hepatocellular carcinoma. The patients in SIRveNIB were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation. "Each year we are making good progress in treating liver cancer. The deeper we go in our research the better we are able to understand how the cancer behaves and we are able to widen the treatments options for our patients. The results reinforced our belief that with the right people on the research project, we can get the best results. I am grateful to our partners for collaborating in this study," added Professor Soo Khee Chee, Director of NCCS. "Completion of the investigator-led SIRveNIB study represents a significant milestone in Asia Pacific liver cancer research, and underscores the strong private-public partnership that exists between Sirtex Medical Limited, the National Cancer Centre Singapore and Singapore Clinical Research Institute. We look forward to the presentation of more complete results of SIRveNIB at the impending ASCO Annual Meeting," said Associate Professor Teoh Yee Leong, CEO Singapore Clinical Research Institute. "This is the first time we have completed such a large-scale investigator-led clinical trial in the Asia Pacific region, whose results will be beneficial to liver cancer patients in our region." Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer - cancer that starts in the liver - which is the sixth most-common cancer in the world and the second most-common cause of cancer-related death.[3] It affects mainly patients with cirrhosis from any cause, including viral hepatitis and alcohol abuse. HCC occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in the Asia Pacific region and Southern Europe. When diagnosed in its early stages, HCC can be treated by surgical resection, ablation or liver transplantation with expectation of improved long-term survival. However, these options are not available to the great majority of patients. For patients with unresectable HCC, the outlook is bleak, with survival ranging from a few months to about two years depending largely on the extent of their tumours and state of their liver at the time of diagnosis.[4] No new HCC treatment option has been tested successfully in large studies for almost a decade. National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. http://www.nccs.com.sg Singapore Clinical Research Institute (SCRI) is a National Academic Research Organisation dedicated to enhance the standards of human clinical research. Its mission is to spearhead and develop core capabilities, infrastructure and scientific leadership for clinical research in Singapore. SCRI is a national clinical trials coordination centre that works with National Medical Research Council (NMRC) to assist the Ministry of Health in implementing clinical trials policy and strategic initiatives to support and develop clinical research competencies locally. In driving towards its vision, SCRI collaborates with clinicians to enhance Singapore's clinical research and strengthen its expertise in executing multi-site, multi-national studies and the development of regional clinical research networks. SCRI is a wholly-owned subsidiary of MOH Holdings. http://www.scri.edu.sg SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as Turkey, India and Singapore. The product is also supplied for this use in countries and regions such as Hong Kong, Israel, Malaysia, New Zealand, Taiwan and Thailand. SIR-Spheres Y-90 resin microspheres also have a full Pre-Market Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine. [1] Intent-to-treat group includes all patients who were enrolled and randomly allocated to treatment and are analysed according to the group to which they were randomized.  The intent-to-treat-group included n=182 (Y-90 resin microspheres) and n=178 (sorafenib). [2] Treated group includes only those patients who completed the treatment originally allocated.  The treated group included n=130 (Y-90 resin microspheres) and n=162 (sorafenib). [3] Ferlay J et al.  Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr , accessed on 18/May/2017.

Loading NMRC collaborators
Loading NMRC collaborators